# A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Source: https://onco.cc/trials/nct06754644/  
OnCo record `nct06754644` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing QL2107 in non-small-cell lung cancer, now recruiting.

## Summary

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC is a phase 3 interventional study registered as NCT06754644, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Double-blind, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of QL2107 Versus Keytruda® in Combination With Chemotherapy in the Treatment of Metastatic Non-squamous Non-small-cell Lung Cancer. Planned enrolment is 808 participants (estimated). The study started in 2025-01-15 and primary completion is expected in 2026-12. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06754644
- Phase: 3
- Setting: A Randomized, Double-blind, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of QL2107 Versus Keytruda® in Combination With Chemotherapy in the Treatment of Metastatic Non-squamous Non-small-cell Lung Cancer
- Sponsor: Qilu Pharmaceutical
- Enrolled: 808

## Sources

- ClinicalTrials.gov NCT06754644: https://clinicaltrials.gov/study/NCT06754644

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [QL2107](https://onco.cc/drugs/ql2107/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06754644.json